Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
Standard
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. / Passweg, J R; Baldomero, H; Bader, P; Bonini, C; Cesaro, S; Dreger, P; Duarte, R F; Dufour, C; Kuball, J; Farge-Bancel, D; Kröger, Nicolaus; Gennery, A; Lanza, F; Nagler, A; Sureda, A; Mohty, M.
in: BONE MARROW TRANSPL, Jahrgang 51, Nr. 6, 06.2016, S. 786-92.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
AU - Passweg, J R
AU - Baldomero, H
AU - Bader, P
AU - Bonini, C
AU - Cesaro, S
AU - Dreger, P
AU - Duarte, R F
AU - Dufour, C
AU - Kuball, J
AU - Farge-Bancel, D
AU - Kröger, Nicolaus
AU - Gennery, A
AU - Lanza, F
AU - Nagler, A
AU - Sureda, A
AU - Mohty, M
PY - 2016/6
Y1 - 2016/6
N2 - A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.Bone Marrow Transplantation advance online publication, 22 February 2016; doi:10.1038/bmt.2016.20.
AB - A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.Bone Marrow Transplantation advance online publication, 22 February 2016; doi:10.1038/bmt.2016.20.
U2 - 10.1038/bmt.2016.20
DO - 10.1038/bmt.2016.20
M3 - SCORING: Journal article
C2 - 26901709
VL - 51
SP - 786
EP - 792
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 6
ER -
